Alumis, ACELYRIN amend proposed merger pact
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2025
0mins
Source: SeekingAlpha
Merger Agreement Update: Alumis and ACELYRIN have revised their merger agreement, allowing ACELYRIN shareholders to receive 0.4814 shares of Alumis stock for each share they hold, with the merger expected to close in Q2 2025.
Ownership Distribution and Financial Outlook: Post-merger, Alumis stockholders will own approximately 52% and ACELYRIN stockholders about 48% of the new entity, which is projected to have around $737 million in cash by the end of 2024 to support its operations and clinical trials through 2027.
Analyst Views on ALMS
Wall Street analysts forecast ALMS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is 19.50 USD with a low forecast of 14.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 24.170
Low
14.00
Averages
19.50
High
25.00
Current: 24.170
Low
14.00
Averages
19.50
High
25.00
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
